NewAmsterdam Pharma Company Insiders

NewAmsterdam Pharma Management Team Effectiveness

The company has return on total asset (ROA) of (0.1815) % which means that it has lost $0.1815 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3151) %, meaning that it created substantial loss on money invested by shareholders. NewAmsterdam Pharma's management efficiency ratios could be used to measure how well NewAmsterdam Pharma manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.29 in 2025. Return On Capital Employed is likely to gain to -0.22 in 2025. At this time, NewAmsterdam Pharma's Total Assets are comparatively stable compared to the past year. Net Tangible Assets is likely to gain to about 60.1 M in 2025, whereas Other Current Assets are likely to drop slightly above 6.5 M in 2025. Common Stock Shares Outstanding is likely to drop to about 50.8 M in 2025. Net Loss is likely to drop to about (27 M) in 2025

NewAmsterdam Pharma Workforce Comparison

NewAmsterdam Pharma Insider Trading

NewAmsterdam Pharma Notable Stakeholders

The success or failure of an entity such as NewAmsterdam Pharma often depends on how effective the management is. NewAmsterdam Pharma management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of NewAmsterdam management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the NewAmsterdam management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Please note, the imprecision that can be found in NewAmsterdam Pharma's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of NewAmsterdam Pharma. Check NewAmsterdam Pharma's Beneish M Score to see the likelihood of NewAmsterdam Pharma's management manipulating its earnings.

When running NewAmsterdam Pharma's price analysis, check to measure NewAmsterdam Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NewAmsterdam Pharma is operating at the current time. Most of NewAmsterdam Pharma's value examination focuses on studying past and present price action to predict the probability of NewAmsterdam Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NewAmsterdam Pharma's price. Additionally, you may evaluate how the addition of NewAmsterdam Pharma to your portfolios can decrease your overall portfolio volatility.